{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Early%2FSlow&page=2",
    "query": {
      "intervention": "Early/Slow",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Early%2FSlow&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-14T03:16:15.343Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03085810",
      "title": "Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Multiple Sclerosis, Relapsing-Remitting"
      ],
      "interventions": [
        {
          "name": "Ocrelizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 1225,
      "start_date": "2017-03-24",
      "completion_date": "2023-04-27",
      "has_results": true,
      "last_update_posted_date": "2025-01-15",
      "last_synced_at": "2026-09-14T03:16:15.343Z",
      "location_count": 26,
      "location_summary": "Irvine, California • Sunnyvale, California • Aurora, Colorado + 23 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Sunnyvale",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Fort Collins",
          "state": "Colorado"
        },
        {
          "city": "Stamford",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03085810"
    },
    {
      "nct_id": "NCT05253495",
      "title": "Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-hodgkin Lymphoma",
        "Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "DOC Group B",
          "type": "DRUG"
        },
        {
          "name": "Pv-COMRAD 1 and 2 Group B",
          "type": "DRUG"
        },
        {
          "name": "Pv-R-CYM 1 and 2 Group B",
          "type": "DRUG"
        },
        {
          "name": "DOC Group C",
          "type": "DRUG"
        },
        {
          "name": "MAD CPR 1 and 2",
          "type": "DRUG"
        },
        {
          "name": "Pv-R CYVE 1 and 2",
          "type": "DRUG"
        },
        {
          "name": "Pv-R CYVE-MTX 1 and 2",
          "type": "DRUG"
        },
        {
          "name": "MAD CP",
          "type": "DRUG"
        },
        {
          "name": "Pv-Cytarabine/etoposide",
          "type": "DRUG"
        },
        {
          "name": "AD CP",
          "type": "DRUG"
        },
        {
          "name": "Bv-AVD-R 1 and 2: COHORT IIa",
          "type": "DRUG"
        },
        {
          "name": "Bv-NVD-R, Cycle 1-2",
          "type": "DRUG"
        },
        {
          "name": "Bv-NVD-R, Cycle 1-4 SER",
          "type": "DRUG"
        },
        {
          "name": "Bv-AVD-R",
          "type": "DRUG"
        },
        {
          "name": "Bv-NVD-R, Cycle 1-4 RER",
          "type": "DRUG"
        },
        {
          "name": "Bv-NAVD-R, Cycle 1-2",
          "type": "DRUG"
        },
        {
          "name": "Involved Site Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "New York Medical College",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "39 Years",
        "sex": "ALL",
        "summary": "3 Years to 39 Years"
      },
      "enrollment_count": 80,
      "start_date": "2022-02-01",
      "completion_date": "2028-06-30",
      "has_results": false,
      "last_update_posted_date": "2025-06-13",
      "last_synced_at": "2026-09-14T03:16:15.343Z",
      "location_count": 3,
      "location_summary": "Birmingham, Alabama • Gainsville, Florida • Vallhala, New York",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Gainsville",
          "state": "Florida"
        },
        {
          "city": "Vallhala",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05253495"
    },
    {
      "nct_id": "NCT00802685",
      "title": "Timing of PDA Closure and Respiratory Outcome in Premature Infants",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Patent Ductus Arteriosus"
      ],
      "interventions": [
        {
          "name": "Early ibuprofen",
          "type": "DRUG"
        },
        {
          "name": "Late ibuprofen expectant group (placebo)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Miami",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Day",
        "maximum_age": "14 Days",
        "sex": "ALL",
        "summary": "1 Day to 14 Days"
      },
      "enrollment_count": 105,
      "start_date": "2007-11",
      "completion_date": "2011-02",
      "has_results": true,
      "last_update_posted_date": "2014-02-05",
      "last_synced_at": "2026-09-14T03:16:15.343Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00802685"
    },
    {
      "nct_id": "NCT05348785",
      "title": "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Parkinson Disease"
      ],
      "interventions": [
        {
          "name": "BIIB122",
          "type": "DRUG"
        },
        {
          "name": "BIIB122-Matching Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "30 Years to 80 Years"
      },
      "enrollment_count": 650,
      "start_date": "2022-04-19",
      "completion_date": "2026-03-09",
      "has_results": false,
      "last_update_posted_date": "2026-06-04",
      "last_synced_at": "2026-09-14T03:16:15.343Z",
      "location_count": 33,
      "location_summary": "Phoenix, Arizona • Sun City, Arizona • Los Angeles, California + 25 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05348785"
    },
    {
      "nct_id": "NCT03434730",
      "title": "Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Acute Lymphoblastic Leukemia",
        "Acute Leukemia",
        "Myelodysplastic Syndromes",
        "Myelodysplastic-Myeloproliferative Diseases",
        "Myeloproliferative Disorder",
        "Non Hodgkin Lymphoma",
        "Hodgkin Lymphoma",
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "Total Body Irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        },
        {
          "name": "Tocilizumab",
          "type": "DRUG"
        },
        {
          "name": "Filgrastim",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 46,
      "start_date": "2018-02-07",
      "completion_date": "2025-04-18",
      "has_results": true,
      "last_update_posted_date": "2026-05-26",
      "last_synced_at": "2026-09-14T03:16:15.343Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03434730"
    },
    {
      "nct_id": "NCT06086704",
      "title": "Study of 18F-FFNP Breast PET/MRI",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "18F-fluorofuranylnorprogesterone",
          "type": "DRUG"
        },
        {
          "name": "Positron Emissions Tomography / Magnetic Resonance Imaging",
          "type": "DEVICE"
        },
        {
          "name": "Anastrozole",
          "type": "DRUG"
        },
        {
          "name": "Blood Sampling",
          "type": "OTHER"
        },
        {
          "name": "FDA-approved gadolinium-based intravenous contrast agent",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "University of Wisconsin, Madison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 53,
      "start_date": "2024-09-25",
      "completion_date": "2030-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-31",
      "last_synced_at": "2026-09-14T03:16:15.343Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06086704"
    },
    {
      "nct_id": "NCT00004547",
      "title": "Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Abdominal Neoplasm",
        "Colonic Neoplasm",
        "Mesothelioma",
        "Peritoneal Neoplasm"
      ],
      "interventions": [
        {
          "name": "Surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "Continuous hyperthermic peritoneal perfusion (CHPP) with Cisplatin",
          "type": "PROCEDURE"
        },
        {
          "name": "Postoperative dwell with paclitaxel and 5-FU",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 188,
      "start_date": "2000-01",
      "completion_date": "2009-08",
      "has_results": true,
      "last_update_posted_date": "2015-11-18",
      "last_synced_at": "2026-09-14T03:16:15.343Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004547"
    },
    {
      "nct_id": "NCT03407144",
      "title": "Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "vinblastine",
          "type": "DRUG"
        },
        {
          "name": "dacarbazine",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "vincristine",
          "type": "DRUG"
        },
        {
          "name": "prednisone/prednisolone",
          "type": "DRUG"
        },
        {
          "name": "bleomycin",
          "type": "DRUG"
        },
        {
          "name": "etoposide",
          "type": "DRUG"
        },
        {
          "name": "Radiotherapy (RT)",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "3 Years to 25 Years"
      },
      "enrollment_count": 340,
      "start_date": "2018-04-09",
      "completion_date": "2026-11-06",
      "has_results": false,
      "last_update_posted_date": "2026-02-19",
      "last_synced_at": "2026-09-14T03:16:15.343Z",
      "location_count": 47,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 41 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Downey",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03407144"
    },
    {
      "nct_id": "NCT01719562",
      "title": "MRI in Detecting Heart Damage in Patients With Cancer Receiving Chemotherapy With Exercise Capacity Addendum",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cardiac Toxicity",
        "Malignant Neoplasm",
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Magnetic resonance imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Physical Activity",
          "type": "OTHER"
        },
        {
          "name": "Healthy Living",
          "type": "OTHER"
        },
        {
          "name": "Cardiopulmonary Exercise Testing (CPET)",
          "type": "DEVICE"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER",
        "DEVICE"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 28,
      "start_date": "2013-01-01",
      "completion_date": "2022-03-08",
      "has_results": true,
      "last_update_posted_date": "2023-05-19",
      "last_synced_at": "2026-09-14T03:16:15.343Z",
      "location_count": 2,
      "location_summary": "Winston-Salem, North Carolina • Richmond, Virginia",
      "locations": [
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        },
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01719562"
    },
    {
      "nct_id": "NCT06029244",
      "title": "Eyecontrol coMmunication Platform for dEliRium manaGemEnt in Intensive Care Units (EMERGE)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Delirium",
        "Delirium in Old Age",
        "Critical Illness",
        "Intensive Care Unit Delirium"
      ],
      "interventions": [
        {
          "name": "EyeControl-Pro",
          "type": "DEVICE"
        },
        {
          "name": "Control",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "Beth Israel Deaconess Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 160,
      "start_date": "2024-02-25",
      "completion_date": "2025-11-18",
      "has_results": false,
      "last_update_posted_date": "2025-12-03",
      "last_synced_at": "2026-09-14T03:16:15.343Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06029244"
    }
  ]
}